Source comparison
Peptide Mechanisms: GHRP vs GHRH vs IGF-1 Analogues
Not all muscle-building peptides operate through the same receptor or pathway. Three primary categories exist, each with distinct mechanisms, benefits, and research applications: growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormones (GHR
This comparison does not assign a generated winner or score.
- Not all muscle-building peptides operate through the same receptor or pathway. Three primary categories exist, each with distinct mechanisms, benefits, and research applications: growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormones (GHRHs), and IGF-1 analogues.
- GHRPs—including GHRP-2, GHRP-6, Hexarelin, and Ipamorelin—bind to the ghrelin receptor (GHSR-1a) in the anterior pituitary. This binding triggers intracellular calcium release and activation of protein kinase C, ultimately stimulating somatotroph cells to release stored growth hormone. GHRPs produce dose-dependent GH pulses: 100mcg Ipamorelin can elevate serum GH 2–3× baseline within 30 minutes, returning to baseline within 2–3 hours. The transient nature preserves negative feedback loops—unlike continuous GH infusion, peptide pulses don't suppress hypothalamic GHRH or somatostatin regulation.
- GHRH analogues—most notably CJC-1295 NO DAC and Sermorelin—bind GHRH receptors on pituitary somatotrophs, amplifying the body's natural GH release rhythm rather than creating pharmacological peaks. CJC-1295 (without DAC, or drug affinity complex) has a half-life of approximately 7–10 days due to its ability to bind serum albumin, extending activity without the covalent DAC modification. Sermorelin's half-life is significantly shorter (8–12 minutes), requiring multiple daily administrations for sustained effect. The primary advantage of GHRHs: they work synergistically with GHRPs—combining a GHRP (which stimulates release) with a GHRH (which amplifies release magnitude) produces supra-additive GH output, often 3–5× higher than either compound alone.
- IGF-1 analogues bypass the GH axis entirely. IGF-1 LR3 binds directly to IGF-1 receptors on muscle tissue, activating downstream anabolic pathways without requiring GH secretion or hepatic IGF-1 conversion. This is mechanistically significant for two reasons: first, it allows localized administration (intramuscular injection near target muscle groups), and second, it circumvents age-related declines in GH receptor sensitivity or hepatic IGF-1 production that limit GH efficacy in older populations. Research in sarcopenia models shows IGF-1 LR3 preserved lean mass and contractile function independent of circulating GH levels—suggesting the anabolic signal can be delivered even when upstream hormone production is impaired.
- Our clients frequently ask whether combining categories makes sense. The answer depends on research objectives: GHRP + GHRH combinations maximize pulsatile GH release while preserving natural feedback regulation. IGF-1 analogues provide direct tissue-level anabolic signaling but bypass systemic benefits of GH (lipolysis, collagen synthesis, immune modulation). Stacking all three introduces redundancy and increases metabolic burden without proportional benefit—most research protocols select either a secretagogue combination or an IGF-1 analogue, not both simultaneously.